INTRODUCTION
============

Epstein--Barr virus (EBV) expresses two transcription factors, Rta and Zta, during the immediate-early stage of the lytic cycle, to activate the transcription of EBV lytic genes ([@B1; @B2; @B3; @B4; @B5]). As is well known, Zta, encoded by BZLF1, activates transcription by binding to Zta response elements (ZRE) in promoters. Since the transcription of many EBV lytic genes depends on Zta, EBV cannot complete its lytic cycle after BZLF1 is mutated ([@B6],[@B7]). Meanwhile, Rta commonly binds to a defined sequence, Rta response elements (RRE), in EBV lytic promoters to activate transcription ([@B2],[@B5],[@B8; @B9; @B10; @B11]). However, Rta may activate transcription through a mechanism that is independent of RRE binding. For example, Rta interacts with Sp1 via an intermediary protein, MCAF1, to form a complex on Sp1-binding sites to autoregulate the transcription of its own gene, BRLF1 ([@B12],[@B13]). Furthermore, the transcription of several EBV late genes depends on Rta but not on Zta ([@B6],[@B14; @B15; @B16]), explaining why a mutation in BRLF1 is devastating to viral lytic development ([@B6],[@B7]).

Earlier studies have established that Rta and Zta often collaborate with each other to activate transcription synergistically of many EBV lytic genes, including BHLF1, BMRF1 and BRLF1 ([@B3],[@B5],[@B9],[@B17; @B18; @B19]). Although various studies of the mechanism that underlies synergistic activation have been conducted, exactly how Rta and Zta synergistically activate transcription remains unknown. Since earlier studies have failed to demonstrate an interaction between Rta and Zta ([@B5]), Rta and Zta are assumed to bind to their respective binding sites in a promoter to promote synergistic activation. In fact, Quinlivan *et al.* ([@B5]) posited that synergistic activation depends on the presence of at least one RRE and one ZRE in a promoter. However, the fact that Zta and Rta synergistically activate the BRLF1 promoter ([@B18]), which does not contain an RRE, is evidence against the hypothesis that synergistic activation depends on an RRE. In fact, Ragoczy *et al.* ([@B20]) suggested that the synergistic activation of the BRLF1 promoter by Rta and Zta depends on the binding of an unknown protein to the promoter. Giot *et al.* ([@B4]) also asserted that rather than binding to an RRE, Rta may form a complex with Zta via an intermediary protein to activate transcription synergistically.

As is well known, MCAF1 promotes SETDB1/ESET-mediated histone H3 methylation, thus facilitating the formation of heterochromatin domains ([@B21],[@B22]). MCAF1 also interacts with MBD1 and Sp1 ([@B23]). When interacting with MBD1, MCAF1 promotes MBD1-dependent transcriptional repression ([@B23]). When interacting with Sp1, MCAF1 becomes a coactivator that enhances Sp1-mediated transcription ([@B12],[@B23],[@B24]). An earlier study has demonstrated that Rta interacts with Sp1 through MCAF1 to promote the autoregulation of BRLF1 transcription ([@B12]). This study demonstrates that MCAF1 interacts simultaneously with Rta and Zta. This interaction promotes the synergistic activation of the transcription of the EBV lytic genes.

MATERIALS AND METHODS
=====================

Cell lines and EBV lytic induction
----------------------------------

P3HR1, EBV-negative Akata and BJAB cells were cultured in RPMI 1640 medium that contained 10% fetal calf serum. 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) that contained 10% fetal calf serum. P3HR1 cells were treated with 3 ng/ml of TPA and 3 mM sodium butyrate to activate the EBV lytic cycle ([@B25]).

Plasmids
--------

Plasmids pCMV-3, pCMV-R, pCMV-Z, pSp1-luc, pcDNA-MCAF1, pRRE, pEGFP-Rta, pEGFP-MCAF1-N, pET-Rta and pGEX-Rta have been described elsewhere ([@B12],[@B25]). Plasmids pEGFP-MCAF1-DM1, pEGFP-MCAF1-M and pEGFP-MCAF1-DM2 were constructed by inserting polymerase chain reaction (PCR)-amplified DNA fragments that encoded the MCAF1 regions from amino acid 562 to 817, 818 to 1153 and 1154 to 1270, respectively, into the ScaI--XhoI sites in pEGFP-C1 (Clontech). Plasmids pEGFP-ZN, pEGFP-ZM and pEGFP-ZC, which expressed truncated Zta, were constructed by inserting PCR-amplified fragments that encoded the amino acid regions from 1 to 86, 87 to 166 and 167 to 245, respectively, into the EcoRI--SalI sites in pEGFP-C1. Plasmids pET-Zta and pGEX-Zta were constructed by inserting full-length BZLF1 (n.t. 103155--102211 in the EBV genome) (GenBank accession number V01555), which was amplified by PCR, into the EcoRI--SalI sites in pET-28a (Novagen) and pGEX-4T1 (Amersham Pharmacia Biotech), respectively. A DNA fragment that encoded the region from amino acid 562 to 884 in MCAF1 was inserted into the HindIII--XhoI sites in pGEX-4T1 and pET-32a to yield pGEX-MCAF-C1 and pET-MCAF1-C1, respectively. Plasmid pGEX-MCAF1-C2 was constructed by inserting a PCR-amplified fragment that encoded the region from amino acid 885 to 1270 in MCAF1 into the HindIII--XhoI sites in pGEX-4T1. The synergistic activation by Rta and Zta was studied using reporter plasmids pEAD, pBMRF1, pBMRF1-mRRE, pBMRF1-mZRE, pBHLF1, pRRE and pZRE ([Table 1](#T1){ref-type="table"}). Plasmid pEAD was constructed by inserting a PCR-amplified DNA fragment that contained the −332 to +20 region in BMRF1 (n.t. 79537 to 79889 on the EBV genome) into the HindIII--XhoI sites in pGL2-Basic (Promega). A reporter plasmid, pBMRF1, was constructed by inserting a PCR-amplified DNA fragment that contained the −172 to +20 region in BMRF1 (n.t. 79698 to 79889 on the EBV genome) into the HindIII--XhoI sites in pGL2-Basic. Plasmid pBMRF1-mRRE contains the same sequences as pBMRF1, but with the RRE sequence mutated from 5′-ACACCACCCCCCAAGGAC to 5′-GATATCCCCCCCAAGGAC. Plasmid pBMRF1-mZRE has the same sequence as is present in pBMRF1, but the three ZREs in the promoter, from upstream to downstream, were mutated from 5′-TTGCTCA, 5′-TGAGCAA, and 5′-TGAGTCA to 5′-GGATCCA, 5′-TGGATCC and 5′-CAGCTGA, respectively. Another reporter plasmid, pBHLF1, which includes four copies of ZREs (n.t. 52769 to 52931 on the EBV genome) was constructed by inserting a PCR-amplified fragment into the HindIII and XhoI sites in pGL2-Basic. Plasmid pZRE was constructed by inserting a double-stranded oligonucleotide 5′-AAAGGCCGGCTGACATGGATTACTGGTCTTTTATGAGCCATT, which had the sequence from the −39 to +4 region in the BRLF1 promoter, into the SmaI site in pGL2-Basic. Plasmid pCMV-Sp1 was obtained from Guntram Suske ([@B26]). Plasmid pTag2-Zta was constructed by inserting a PCR-amplified DNA fragment that encodes BZLF1 (n.t. 103155 to 102211 on the EBV genome) to the EcoRI and XhoI sites of pCMV-Tag2A (Stratagene). Moreover, plasmid pCMV-R(K213A) encoded a mutant Rta that contained a K213A mutation ([@B12]). Table 1.Reporter plasmids used in this study![](gkq243i1.jpg)[^1][^2][^3]

DNA-affinity precipitation assay
--------------------------------

A 5′-biotin end-labeled double-stranded DNA probe, Rp-SZ, which contained the sequence from −64 to −28 in the BRLF1 promoter (5′-ATATTGCGATTGTCCCGCCCATGCCAATGGCTCATAA), was synthesized by Mission Biotech, Inc. (Taipei, Taiwan). This sequence includes an Sp1-binding site (5′-CCGCCC) and a ZRE (5′-TGGCTCA). Probes Rp-mS and Rp-mZ included the same sequence as Rp-SZ except that the Sp1 site and ZRE were mutated to 5′-ATTAAT and 5′-GACTGCA, respectively. In probe Rp-mSZ, both the Sp1 site and the ZRE were mutated. Probe MRp-RZ contained the sequence between the region −174 and −36 in the BMRF1 promoter and, then, was amplified by PCR using biotinylated primers. In this probe, the RRE was mutated from 5′-ACACCACCCCCCAAGGAC to 5′-GATATCCCCCCCAAGGAC to generate a probe, MRp-mR; the three ZREs, 5′-TTGCTCA, 5′-TGAGCAA and 5′-TGAGTCA to 5′-GGATCCA, 5′-TGGATCC and 5′-CAGCTGA, respectively, to generate MRp-mZ. In the probe MRp-mRZ, RRE and ZREs were all mutated. Probe HLp-Z (5′-GTCTCTGTGTAATACTTTAAGGTTTGCTCAGGAG) contained two ZREs, 5′-TGTGTAA and 5′-TTGCTCA, from the BHLF1 promoter. In probe HLp-mZRE, these two ZRE sites were both mutated to 5′-TGGTATA. Probe MLp-R had an RRE sequence that was taken from the BMLF1 promoter; in MLp-mR, the RRE sequence was mutated, as described elsewhere ([@B12]). A cell lysate prepared from P3HR1 cells that had been treated with sodium butyrate and TPA was mixed with 0.2 μg of a biotinylated probe in a binding buffer that contained 60 mM KCl, 12 mM HEPES, pH 7.9, 4 mM Tris--HCl, 5% glycerol, 0.5 mM EDTA, 1 mM dithiothreitol and 10 μg/ml each of leupeptin, aprotinin, and 4-(2-aminoethyl)-benzenesulfonyl fluoride. After it had been incubated on ice for 45 min, the reaction mixture was mixed with 30 μl Streptavidin MagneSphere Paramagnetic particles (Promega), which had been pre-equilibrated in the binding buffer for 1 h at 4°C. The beads were then washed five times in the binding buffer. The proteins on the beads were then extracted using 2X electrophoresis sample buffer and boiled for 5 min. Finally, they were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and detected by immunoblotting ([@B25]).

Immunoprecipitation
-------------------

P3HR1 cells (1 × 10^7^) were treated with TPA and sodium butyrate for 24 h. A lysate was prepared from the cell using radioimmune precipitation assay (RIPA) buffer ([@B25]), followed by three times of sonication under the conditions of 10-s pulses with 10-s cooling at 20% power using a sonicator (Vibra Cell, Sonics) equipped with a microprobe. The lysate was centrifuged at 13 800 *g* for 5 min and the supernatant was mixed with anti-Rta (1:3000 dilution) (Argene), anti-Zta (1:1000) (Argene) or anti-MCAF1 (1:1000) (Bethyl) antibody at 4°C for 1 h. Protein-A/G agarose beads (30 μl) (Oncogene) were added to the lysate and the mixture was incubated with shaking for 1 h at 4°C. The beads were collected by centrifugation and washed three times in RIPA buffer. Proteins binding to the beads were eluted by adding 20 μl of 2X electrophoresis sample buffer and analyzed by immunoblotting with anti-Rta, anti-Zta, anti-MCAF1 or anti-GFP (Santa Cruze) antibody.

Glutathione S-transferase-pull-down assay
-----------------------------------------

GST, GST-Zta, GST-Rta, GST-MCAF1-C1 or GST-MCAF1-C2 at a concentration of 40 ng/ml in 500 μl NETN buffer \[20 mM Tris--HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40 and 10 μg/ml each of leupeptin, aprotinin and 4-(2-aminoethyl)-benzenesulfonyl fluoride\] was added to 30 μl glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). The mixture was incubated with shaking for 1 h at 4°C. The beads were washed three times in NETN buffer and added to the *Escherichia coli* BL21(DE3)(pET-MCAF1-C1), *E. coli* BL21(DE3)(pET-Zta) or *E. coli* BL21(DE3)(pET-Rta) lysate. The reaction mixture was incubated on ice for 1 h. The beads were then washed in NETN buffer. An equal volume of 2X electrophoresis sample buffer was added to the mixture and proteins were extracted from the beads by heating at 95°C for 5 min. Proteins were then separated by SDS-polyacrylamide gel electrophoresis ([@B27]).

Chromatin immunoprecipitation assay
-----------------------------------

Chromatin immunoprecipitation (CHIP) assay was performed using a method described elsewhere ([@B28]). P3HR1 cells (1 × 10^7^) were treated with TPA and sodium butyrate to induce the expression of Rta and Zta. DNA--protein complex that was cross-linked by formaldehyde was immunoprecipitated with anti-Rta, anti-Zta or anti-MCAF1 antibodies after the DNA had been fragmented by sonication. The presence of specific DNA fragments in the precipitates was detected by qPCR. Primers used for amplifying the BHLF1 promoter were 5′-TCGCCTTCTTTTATCCTCTTTTTG and 5′-CCCAACGGGCTAAAATGACA; BHRF1, 5′-CGCGTGCCTTACTGACTTGTC and 5′-CCAGGAAGTGGCGAGCAT; BMRF1, 5′-GCCCGCTCACCTACATGAC and 5′-GCAGCAGCAGAAGCCAAC; BMLF1, 5′-CCAGATGTCCCTCTATCA and 5′-AACCTCTTACATCACTCAC. Quantitative PCR was performed on the products of CHIP in triplicate by the SYBR Green method using the Power SYBR Green PCR Master Mix and StepOne Real-Time PCR system (Applied Biosystems). Standard curves were generated using serial dilutions of input DNA (100, 10, 1 and 0.1%). The Ct of each reaction was quantified against the standard curve.

Immunofluorescence analysis
---------------------------

P3HR1 cells were transfected with pEGFP-Rta. After they had been cultured for 24 h, the cells were harvested by centrifugation, plated on poly-L-Lysine (Sigma)-coated coverslips, and fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min. Immunostaining was performed using anti-Zta monoclonal antibody and rabbit anti-MCAF1 polyclonal antibody and then the cells were treated with fluorescein isothiocyanate (FITC)-conjugated donkey anti-mouse IgG polyclonal antibody (KPL), or rhodamine-conjugated donkey anti-rabbit IgG polyclonal antibody (DAKO), using a method described elsewhere ([@B27]). Nuclei were visualized by staining with 5 μg/ml 4′-6-diamidino-2-phenylindole (DAPI). After staining, the cells were observed under an Olympus confocal laser-scanning microscope (Model Fluoview 500).

Transient transfection assay
----------------------------

P3HR1 and 293T cells (5 × 10^6^) were transfected with 5 μg of plasmids at 240 V, 975 μF by electroporation using a BTX ECM630 electroporator (BTX Instrument). To suppress MCAF1 expression, 293T cells (1 × 10^4^) were transfected with 0.3 μg pBHLF1, pEAD and 50 pmol siRNA MCAF1 or control siRNA (Invitrogen primer number 130189C06) with Lipofectamin 2000 (Invitrogen). Luciferase assay was performed using a luminometer (Orion II; Berthod) as described elsewhere ([@B29]). Each transfection experiment was performed at least three times, and each sample in the experiment was prepared in duplicate.

RESULTS
=======

Binding of Zta, MCAF1 and Rta to a ZRE in lytic promoters
---------------------------------------------------------

This work used four different biotinylated probes, Rp-SZ, Rp-mS, Rp-mZ and Rp-mSZ ([Figure 1](#F1){ref-type="fig"}A), to study the binding of MCAF1, Rta, Sp1 and Zta to an Sp1 site and a ZRE in the BRLF1 promoter. A lysate was prepared from P3HR1 cells that were treated with 12-*O*-tetradecanoylphorbol-13-acetate (TPA) and sodium butyrate to induce the EBV lytic cycle and the expression of Rta and Zta. Immunoblotting revealed that Sp1, MCAF1, Rta and Zta were present in the cell lysate ([Figure 1](#F1){ref-type="fig"}B, lanes 1 and 4). Our earlier study found that Rta, MCAF1 and Sp1 form a complex on Sp1 sites ([@B12]). Therefore, as expected, this study found the binding of Rta and MCAF1 to probes Rp-SZ and Rp-mZ ([Figure 1](#F1){ref-type="fig"}B, lanes 2 and 6) because both probes contained an Sp1 site ([Figure 1](#F1){ref-type="fig"}A). Meanwhile, Zta bound to Rp-SZ but not Rp-mZ ([Figure 1](#F1){ref-type="fig"}B, lanes 2 and 6) because in Rp-mZ, the ZRE was mutated ([Figure 1](#F1){ref-type="fig"}A). This study also analyzed the binding of these proteins to Rp-mS, which contained a mutated Sp1 site ([Figure 1](#F1){ref-type="fig"}A). Although Sp1 did not bind to the probe, immunoblot analysis revealed the binding of MCAF1, Rta and Zta ([Figure 1](#F1){ref-type="fig"}B, lane 3). Additionally, these three proteins did not bind to the probe after the Sp1 site and ZRE were both mutated (Rp-mSZ) ([Figure 1](#F1){ref-type="fig"}A and B, lane 7), suggesting that Rta and MCAF1 interact with not only the Sp1 on the Sp1 site but also the Zta on ZRE. This study also investigated the binding of Rta, MCAF1 and Zta in the BMRF1 promoter. The region between −174 and −36 in the BMRF1 promoter, MRp-RZ, contained one RRE and three ZREs ([Figure 1](#F1){ref-type="fig"}C). Immunoblot analysis revealed the binding of Rta, MCAF1 and Zta to a biotinylated MRp-RZ ([Figure 1](#F1){ref-type="fig"}D, lane 2). These results further indicated that mutating the RRE in the probe, MRp-mR ([Figure 1](#F1){ref-type="fig"}C), did not affect the binding of these three proteins ([Figure 1](#F1){ref-type="fig"}D, lane 3). However, MCAF1 and Zta did not bind to the mutant probe, MRp-mZ ([Figure 1](#F1){ref-type="fig"}D, lane 4), in which the three ZREs were mutated ([Figure 1](#F1){ref-type="fig"}C); although the binding of Rta to the mutant probe was detected ([Figure 1](#F1){ref-type="fig"}D, lane 4). Following mutation of the RRE and ZREs in the probe (MRp-mRZ) ([Figure 1](#F1){ref-type="fig"}C), Rta, MCAF1 and Zta no longer bound to the probe ([Figure 1](#F1){ref-type="fig"}D, lane 5). These results suggested that Rta, MCAF1 and Zta formed a complex on ZRE. This study used another ZRE probe, HLp-Z, which contained the region from −74 to −41 in the BHLF1 promoter, and showed the binding of these three proteins to the probe ([Figure 1](#F1){ref-type="fig"}E, lane 2). However, these proteins did not bind to the probe after the ZRE was mutated (HLp-mZ) ([Figure 1](#F1){ref-type="fig"}E, lane 3), verifying the binding of Rta, MCAF1 and Zta to ZRE. When another probe, MLp-R, which contained an RRE from the BMLF1 promoter, was utilized, only the binding of Rta was detected ([Figure 1](#F1){ref-type="fig"}E, lane 5). Furthermore, Rta did not bind to the probe after the RRE was mutated ([Figure 1](#F1){ref-type="fig"}E, lane 6), indicating that MCAF1 and Zta do not interact with the Rta that binds to an RRE. Furthermore, the BMLF1 promoter is known to contain a sequence resembling that of ZRE ([Table 1](#T1){ref-type="table"}). However, Zta does not appear to activate the promoter ([@B30]). Our result showed that Zta did not bind to the MLp-mR probe, suggesting that the lack of activation is likely attributed to the inability of Zta to bind to this ZRE-like sequence ([Figure 1](#F1){ref-type="fig"}E, lane 6). Figure 1.Binding of Zta, MCAF1 and Rta to ZRE. (**A**) Probe Rp-SZ contains the sequence from −64 to −28 in the BRLF1 promoter. It also includes an Sp1 site (oval) and ZRE (rectangle). Probes Rp-mS, Rp-mZ and Rp-mSZ have the same sequence as Rp-SZ, except that the Sp1 site and ZRE in Rp-SZ were mutated as indicated by a crossed rectangle and a crossed oval. The number represents the nucleotide position relative to the transcriptional start site, '+1' (arrow). 'TATA' represents TATA box. (**C**) A probe, MRP-RZ, contained the region between −174 and −36 in the BMRF1 promoter. Probes MRP-mR, MRP-mZ and MRP-mRZ contained a mutated RRE, ZREs and both RRE and ZREs as indicated by crossed rectangles. (**E**) Probe HLp-Z contained a ZRE from the BHLF1 promoter. In HLp-Z, the ZRE was mutated. (**B, D, E**) The probes were added to a lysate from P3HR1 cells that had been treated with TPA and sodium butyrate. Proteins that were bound to the probes were captured using streptavidin magnetic beads and analyzed by immunoblotting with anti-MCAF1, anti-Rta, anti-Sp1 and anti-Zta antibodies.

Co-immunoprecipitation of Zta, MCAF1 and Rta
--------------------------------------------

Our earlier study demonstrated that Rta and MCAF1 interact and the Rta--MCAF1 complex can be co-immunoprecipitated from a lysate ([@B12]). This study conducted a similar study to investigate the interaction between Zta and MCAF1. Immunoblot analysis revealed that MCAF1 in the P3HR1 lysate ([Figure 2](#F2){ref-type="fig"}A, lane 1) was immunoprecipitated by anti-MCAF1 antibody ([Figure 2](#F2){ref-type="fig"}A, lane 4) and co-immunoprecipitated by anti-Zta antibody ([Figure 2](#F2){ref-type="fig"}A, lane 3). A parallel experiment found that Zta in the lysate ([Figure 2](#F2){ref-type="fig"}A, lane 5) was immunoprecipitated by anti-Zta antibody ([Figure 2](#F2){ref-type="fig"}A, lane 8) and co-immunoprecipitated with MCAF1 by anti-MCAF1 antibody ([Figure 2](#F2){ref-type="fig"}A, lane 7). On the other hand, Zta and MCAF1 were not immunoprecipitated by anti-IgG antibody ([Figure 2](#F2){ref-type="fig"}A, lanes 2 and 6). These results showed Zta and MCAF1 interact *in vivo*. A similar study revealed that Rta in the lysate ([Figure 2](#F2){ref-type="fig"}B, lane 1) was immunoprecipitated by anti-Rta antibody ([Figure 2](#F2){ref-type="fig"}B, lane 3) and co-immunoprecipitated by anti-Zta antibody ([Figure 2](#F2){ref-type="fig"}B, lane 4). Zta in the cell lysate ([Figure 2](#F2){ref-type="fig"}B, lane 5) was immunoprecipitated by anti-Zta antibody ([Figure 2](#F2){ref-type="fig"}B, lane 8) and co-immunoprecipitated with Rta by anti-Rta antibody ([Figure 2](#F2){ref-type="fig"}B, lane 7). In negative controls, neither Rta nor Zta was immunoprecipitated by anti-IgG antibody ([Figure 2](#F2){ref-type="fig"}B, lanes 2 and 6). Figure 2.Interaction among Zta, MCAF1 and Rta *in vivo*. (**A**) P3HR1 cells were treated with TPA and sodium butyrate. Proteins in the lysate (lanes 1 and 5) were immunoprecipitated (IP) with anti-IgG (lanes 2 and 6), anti-MCAF1 (lanes 4 and 7) and anti-Zta (lanes 3 and 8) antibodies. Immunoprecipitated proteins were analyzed by immunoblotting (IB) with anti-MCAF1 (lanes 1--4) and anti-Zta (lanes 5--8) antibodies. (**B**) Proteins in the lysate (lanes 1 and 5) were immunoprecipitated with anti-IgG (lanes 2 and 6), anti-Rta (lanes 3 and 7) and anti-Zta (lanes 4 and 8) antibodies. Immunoprecipitated proteins were detected by immunoblotting with anti-Rta (lanes 1--4) and anti-Zta (lanes 5--8) antibodies. Lane 1 in (A) and (B) was loaded with 1% of the cell lysate. Lane 5 in (A) and (B) was loaded with 3% of the cell lysate.

Binding of Zta--MCAF1--Rta complex to ZRE *in vivo*
---------------------------------------------------

P3HR1 cells were treated with TPA and sodium butyrate to induce the expression of Rta and Zta. After cross-linked protein--DNA complex was immunoprecipitated with anti-Zta, anti-MCAF1 and anti-Rta antibodies, PCR with primers that were complimentary to the sequences that flanked the ZRE region in the BHLF1 promoter revealed that DNA fragments that contained the BHLF1 promoter were immunoprecipitated by these three antibodies. The amount of promoter captured by anti-Zta, anti-MCAF1 and anti-Rta antibody exceeded that from the reaction without adding an antibody, the negative control ([Figure 3](#F3){ref-type="fig"}A). Adding the anti-IgG antibody immunoprecipitated the promoter DNA at a level comparable to that of the negative control ([Figure 3](#F3){ref-type="fig"}A). Similar results were also found for the BHRF1 and BMRF1 promoters ([Figure 3](#F3){ref-type="fig"}B and C). However, qPCR revealed that amount of BMLF1 promoter DNA immunoprecipitated by anti-Rta antibody was significantly higher than that immunoprecipitated by anti-Zta and anti-MCAF1 antibodies ([Figure 3](#F3){ref-type="fig"}D). Zta and MCAF1 did not appear to bind to the ZRE in the promoter. Figure 3.Quantitation of the binding of Zta, MCAF1, and Rta to the ZREs in the promoters of BHLF1 (**A**), BHRF1 (**B**), BMRF1 (**C**) and BMLF1 (**D**). P3HR1 cells were treated with TPA and sodium butyrate. The binding of Zta, MCAF1 and Rta to the ZREs was investigated by CHIP analysis using anti-Zta, anti-MCAF1 and anti-Rta antibodies and by qPCR. The reaction was performed with and without the addition of anti-IgG antibody as negative controls. The error bar represents standard error.

Subcellular localization of Rta, MCAF1 and Zta
----------------------------------------------

Our earlier study demonstrated the colocalization between Rta and MCAF1 by confocal microscopy ([@B12]). The same analysis was performed to study the localization of Zta, MCAF1 and Rta. After pEGFP-Rta was transfected into TPA-sodium butyrate-treated P3HR1 cells, GFP-Rta was observed in both the nucleus and the cytoplasm ([Figure 4](#F4){ref-type="fig"}B); Zta was present only in the nucleus ([Figure 4](#F4){ref-type="fig"}C). The merged image revealed that GFP-Rta and Zta colocalized in the nucleus ([Figure 4](#F4){ref-type="fig"}D). GFP expressed from pEGFP was distributed in both the nucleus and the cytoplasm ([Figure 4](#F4){ref-type="fig"}F) and no colocalization between Zta and GFP was observed ([Figure 4](#F4){ref-type="fig"}H). Meanwhile, after TPA and sodium butyrate treatment, Zta that was expressed from the EBV genome was found to colocalize with MCAF1 in the nucleus ([Figure 4](#F4){ref-type="fig"}J--L). Colocalization was not observed when cells were untreated with TPA and sodium butyrate ([Figure 4](#F4){ref-type="fig"}N--P). Figure 4.Subcellular localization of MCAF1, Rta and Zta. P3HR1 cells were transfected with pEGFP-Rta (**A--D**) or an empty vector, pEGFP (**E--H**), and treated with TPA and sodium butyrate (SB). Cells were also treated (**I--L**) or untreated (**M--P**) with TPA and sodium butyrate without transfection. Cells were incubated with monoclonal anti-Zta antibody (C, G, K and O) and rabbit anti-MCAF1 polyclonal antibody (J and N). DAPI staining revealed the nucleus (A, E, I, M). Cells were observed under a confocal laser-scanning microscope. D, H, L and P are merged images.

Mapping interaction domains in Zta and MCAF1
--------------------------------------------

A co-immunoprecipitation experiment was performed to delineate the regions in Zta that interact with MCAF1. 293T cells were cotransfected with plasmids that expressed GFP-ZN, GFP-ZM and GFP-ZC ([Figure 5](#F5){ref-type="fig"}A). Immunoblotting using anti-GFP antibody revealed the presence of GFP-ZN ([Figure 5](#F5){ref-type="fig"}B, lane 1), GFP-ZM ([Figure 5](#F5){ref-type="fig"}B, lane 2) and GFP-ZC ([Figure 5](#F5){ref-type="fig"}B, lane 3) in the lysate, and the co-immunoprecipitation of GFP-ZN ([Figure 5](#F5){ref-type="fig"}B, lane 4), GFP-ZC ([Figure 5](#F5){ref-type="fig"}B, lane 6) but not GFP-ZM ([Figure 5](#F5){ref-type="fig"}B, lane 5) with MCAF1 by anti-MCAF1 antibody ([Figure 5](#F5){ref-type="fig"}B, lanes 4--6), indicating that MCAF1 interacts with the transactivation domain and the region that contains the DNA-binding and dimerization domains in Zta ([Figure 5](#F5){ref-type="fig"}A). Exactly how MCAF1 fragments interact with Zta was also investigated. To do so, plasmids that expressed truncated GFP-MCAF1 fusion proteins ([Figure 5](#F5){ref-type="fig"}C) were transfected into P3HR1 cells that had been treated with TPA and sodium butyrate. After transfection, these proteins were expressed and present in the cell lysate ([Figure 5](#F5){ref-type="fig"}D, lanes 1--4). Immunoblot analysis indicated that GFP-fusion proteins that contain the regions from amino acid 562 to 816 and 1154 to 1270 in MCAF1 (GFP-MCAF1-DM1 and GFP-MCAF1-DM2) were co-immunoprecipitated with Zta by anti-Zta antibody ([Figure 5](#F5){ref-type="fig"}D, lanes 6 and 8). However, GFP fusion proteins that contained the regions from amino acid 1 to 561 (GFP-MCAF1-N) ([Figure 5](#F5){ref-type="fig"}D, lane 5) and from 817 to 1153 (GFP-MCAF1-M) ([Figure 5](#F5){ref-type="fig"}D, lane 7) in MCAF1 were not co-immunoprecipitated, indicating that Zta interacts with domains 1 and 2 in MCAF1 that also interact with Sp1, MBD1, and TFIIE ([@B23],[@B24]). Additionally, in GST-pull-down assay, both GST-MCAF1-C1- and GST-MCAF1-C2-glutathione-Sepharose beads ([Figure 5](#F5){ref-type="fig"}C) were found to pull down His-Zta from an *E. coli* lysate ([Figure 5](#F5){ref-type="fig"}E, lanes 4 and 5). However, GST- or GST-Rta-glutathione-Sepharose beads did not pull down His-Zta ([Figure 5](#F5){ref-type="fig"}E, lanes 2 and 3). GST-Zta-glutathione-Sepharose beads also did not pull down His-Rta from bacterial lysate ([Figure 5](#F5){ref-type="fig"}E, lane 7), suggesting that Rta and Zta do not interact. Our earlier work demonstrated that Rta interacts with domain 1 in MCAF1, which also interacts with Zta ([Figure 5](#F5){ref-type="fig"}D, lane 6), therefore, a bacterial lysate containing His-MCAF1-C1 was added to the lysate mixture that contained GST-Zta and His-Rta. Immunoblotting revealed that adding His-MCAF1-C1 enabled GST-Zta-glutathione-Sepharose beads to pull down His-Rta ([Figure 5](#F5){ref-type="fig"}E, lane 8), indicating that the interaction between Rta and Zta involves domain 1 in MCAF1. Figure 5.Mapping the interaction domains in MCAF1 and Zta. (**A**) Various regions in Zta were fused with GFP. Numbers represent the positions of amino acid in Zta. TA, transactivation domain; DBD, DNA-binding domain; DIM, dimerization domain. (**B**) Plasmids that expressed GFP-ZN (lanes 1 and 4), GFP-ZM (lanes 2 and 5) and GFP-ZC (lanes 3 and 6) were transfected into 293T cells. Proteins in the lysates were analyzed by immunoblotting (IB) with anti-GFP antibody (lanes 1--3). Proteins in the lysate were immunoprecipitated with anti-MCAF1 antibody and examined by IB with anti-GFP antibody (lanes 4--6). (**C**) Plasmids that expressed a segment of MCAF1 that was fused with GFP were used to identify the region in MCAF1 that interacted with Zta. Numbers represent positions of amino acids in MCAF1. Domains 1 and 2 were delineated by Fujita *et al.* ([@B23]). (**D**) The plasmids were transfected into P3HR1 cells that were treated with TPA and sodium butyrate. Proteins in the cell lysate that contained GFP-MCAF1-N (lane 1), GFP-MCAF1-DM1 (lane 2), GFP-MCAF1-M (lane 3) and GFP-MCAF1-DM2 (lane 4) were detected by IB with anti-GFP antibody (lanes 1--4). Proteins in the lysate were immunoprecipitated with anti-Zta antibody and analyzed by immunoblotting with anti-GFP antibody (lanes 5--8). (**E**) The lysate from *E. coli* BL21(DE3)(pET-Zta) was mixed with GST-Rta-, GST-MCAF1-C1-, GST-MCAF1-C2- or GST-glutathione-Sepharose-beads. Proteins that were bound to beads were detected by immunoblotting using anti-Zta antibody (lanes 1--5). *E. coli* lysates that contained His-Rta, His-MCAF1-C1 and His were mixed with GST-Zta-glutathione-Sepharose beads. Proteins that were pulled down by the beads were examined by IB with anti-Rta antibody (lanes 6--8). Lanes 1 and 6 were loaded with 0.5% of the lysate. Lane 9 shows the immunoblot of His-MCAF1-C1 that was purified by Ni-NTA agarose beads.

ZRE and synergistic activation by Rta and Zta
---------------------------------------------

A reporter plasmid, pBMRF1, which contains a firefly luciferase gene transcribed from the BMRF1 promoter was adopted to elucidate how Rta and Zta synergistically activate transcription. The BMRF1 promoter in this reporter plasmid contained an RRE and three ZREs ([Figure 6](#F6){ref-type="fig"}A). In a negative control, this study found that in 293T cells, transfecting an empty vector, pCMV-3, did not activate the BMRF1 promoter in pBMRF1; the luciferase activity exhibited by the reporter plasmid was at a background level ([Figure 6](#F6){ref-type="fig"}B). However, the luciferase activity exhibited by the reporter plasmid increased 58-fold when the cells were cotransfected with pCMV-R ([Figure 6](#F6){ref-type="fig"}B), indicating that Rta activates the BMRF1 promoter. A similar experiment demonstrated that transfecting pCMV-Z increased the luciferase activity exhibited by the reporter plasmid 30-fold ([Figure 6](#F6){ref-type="fig"}B), indicating that Zta also activate the BMRF1 promoter. Additionally, the luciferase activity was 784-fold higher than that of the negative control after cotransfecting with pCMV-R and pCMV-Z ([Figure 6](#F6){ref-type="fig"}B), indicating that Rta and Zta synergistically activate the BMRF1 promoter. A similar study was performed with pBMRF1-mRRE ([Figure 6](#F6){ref-type="fig"}A). In this reporter plasmid, the RRE in the BMRF1 promoter in pBMRF1 was mutated ([Figure 6](#F6){ref-type="fig"}A). After cotransfecting with this reporter plasmid and pCMV-R into 293T cells, the luciferase activity exhibited by the reporter plasmid was 28-fold higher than that exhibited by the negative control ([Figure 6](#F6){ref-type="fig"}B). Meanwhile, luciferase activity increased 21-fold after the cells were cotransfected with pCMV-Z ([Figure 6](#F6){ref-type="fig"}B). The 28-fold activation by Rta of the mutant promoter is unsurprising since Rta often nonspecifically activates transcription from an empty vector ([@B18]). Despite the RRE mutation, cotransfecting 293T cells with pCMV-R and pCMV-Z synergistically increased the activity of the promoter by a factor of 400 ([Figure 6](#F6){ref-type="fig"}B). Moreover, the three ZREs in the promoter were mutated (pBMRF1-mZRE) ([Figure 6](#F6){ref-type="fig"}A). Although pCMV-Z did not activate the mutant promoter, transfecting pCMV-R increased the promoter activity 45-fold in 293T cells ([Figure 6](#F6){ref-type="fig"}B), a level resembling that achieved using pBMRF1. On the other hand, cotransfecting pCMV-R and pCMV-Z into the cells increased the luciferase activity of the reporter plasmid by only 19-fold; less than that achieved using pCMV-R ([Figure 6](#F6){ref-type="fig"}B). The drop in Rta-activated promoter activity from 45-fold to 19-fold associated with transfecting pCMV-Z ([Figure 6](#F6){ref-type="fig"}B) is consistent with the finding of Giot and Quinlivan *et al.* ([@B4],[@B5]), which showed that Zta unbound to ZRE inhibits transcription activation of the BMRF1 promoter by Rta. The DNA-binding domain in Rta is located in the N-terminal region of a protein from amino acid 1 to 320 ([@B31]). Our earlier study demonstrated that an Rta mutant containing a mutation with a K213A mutation in this region does not bind to RRE ([@B12]). This study further demonstrated that the synergy is independent of the binding of Rta to RRE by conducting similar reporter analysis of the BMRF1 promoter in 293T cells with a plasmid, pCMV-R(K213A), that expressed Rta(K213A). Luciferase assay revealed that pCMV-R(K213A) alone activated the BMRF1 promoter 3-fold ([Figure 6](#F6){ref-type="fig"}C). However, Flag-Zta expressed from pTag2-Zta, activated the promoter 194-fold ([Figure 6](#F6){ref-type="fig"}C). Additionally, cotransfecting pCMV-R(K213A) and pTag2-Zta synergistically activated the promoter 685-fold ([Figure 6](#F6){ref-type="fig"}C). Moreover, two reporter plasmids, pRRE and pZRE, which contain an RRE and a ZRE from the BMLF1 and BRLF1 promoters, respectively, were also used. Cotransfecting 293T cells with pRRE and pCMV-R increased the activity of the promoter by a factor of 11 ([Figure 6](#F6){ref-type="fig"}D); cotransfecting pCMV-Z did not increase the activity of the RRE promoter ([Figure 6](#F6){ref-type="fig"}C). The activity of the RRE promoter increased 12-fold after cotransfecting pCMV-R and pCMV-Z ([Figure 6](#F6){ref-type="fig"}D) into the cells, revealing that Rta and Zta do not activate the RRE promoter synergistically. However, although pCMV-R and pCMV-Z increased the promoter activity of pZRE 4.6-fold and 13-fold, respectively, after both plasmids were cotransfected, the activity of the ZRE promoter increased by 107-fold, indicating that Rta and Zta synergistically increase the activity of the ZRE promoter. Furthermore, immunoblot analysis revealed that after cotransfecting pCMV-R and pCMV-Z, pCMV-R did not affect the expression of Zta from pCMV-Z and *vice versa* ([Figure 6](#F6){ref-type="fig"}E), suggesting that the synergistic activation observed is not attributable to an elevated Rta or Zta expression after cotransfection. Figure 6.ZRE and synergistic activation by Rta and Zta. (**A**) A reporter plasmid, pBMRF1, contains a luciferase gene that is transcribed from the −172 to +20 region in BMRF1. In this region, the BMRF1 promoter contains an RRE and three ZREs. In pBMRF1-mRRE and pBMRF1-mZRE, the RRE and ZREs, respectively, are mutated. RRE and ZRE are represented as empty boxes. Mutant sequences are shown as crossed rectangles. (**B**) 293T cells were cotransfected with the reporter plasmids, pCMV-R and pCMV-Z. Cells that were transfected with pCMV-3 were used as a control. (**C**) 293T cells were also cotransfected with pBMRF1 and pCMV-R(K213A), pTag2-Zta or pCMV-3. (**D**) Plasmid pRRE contained an RRE from the BMLF1 promoter and pZRE contained a ZRE from the BRLF1 promoter. 293T cells were cotransfected with the reporter plasmids, pCMV-R, pCMV-Z and pCMV-3. The luciferase activity of the cells was determined at 24 h after transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared in duplicate. (**E**) 293T cells were transfected with pCMV-3, pCMV-R, pCMV-Z or cotransfected with pCMV-R and pCMV-Z. Rta, Zta and α-tubulin expressed by the cells were examined by immunoblotting.

Involvement of MCAF1 in synergistic activation of EBV lytic promoters by Rta and Zta
------------------------------------------------------------------------------------

Two reporter plasmids, pBHLF1 and pEAD, were employed herein to study how MCAF1 affects synergistic activation. In the case of pBHLF1, pCMV-R increased the activity of the promoter 4.7-fold; pCMV-Z increased its activity 94-fold; pCMV-R and pCMV-Z, when cotransfected, increased its activity 524-fold ([Figure 7](#F7){ref-type="fig"}A) in 293T cells. Meanwhile, pCMV-R increased the activity of the BMRF1 promoter in pEAD 83-fold, pCMV-Z increased it 113-fold and pCMV-R and pCMV-Z increased it 558-fold ([Figure 7](#F7){ref-type="fig"}A) in 293T cells. These results indicated that Rta and Zta synergistically activate both the BHLF1 and BMRF1 promoters. Additionally, transfecting the cells with pcDNA-MCAF1 increased Zta-activated BHLF1 transcription from 41.6-fold to 73.7-fold ([Figure 7](#F7){ref-type="fig"}A), indicating that MCAF1, although does not collaborate with Zta to activate transcription synergistically, promotes the transcription that is activated by Zta. Meanwhile, cotransfecting the cells with pcDNA-MCAF1 increased the transcriptional activity of the BHLF1 and the BMRF1 promoters that is synergistically activated by Rta and Zta in a dose-dependent manner. When cells were transfected with 0.5 μg of pcDNA-MCAF1, the promoter activity increased 2.8-fold and 3.8-fold, respectively ([Figure 7](#F7){ref-type="fig"}B). A similar phenomenon was also found in a B lymphocyte cell line, BJAB. Overexpressing Rta and Zta in the cells activated the BMRF1 promoter in pEAD 35- and 15-fold, respectively; in addition, overexpressing both proteins synergistically activated the promoter 667-fold ([Figure 7](#F7){ref-type="fig"}C). Expressing MCAF1 by transfection also enhances the synergistic activation in a dose-dependent manner. In a cotransfection experiment, the synergistic activation was further enhanced 2.6-, 3.0- and 4.1-fold when 0.1, 0.3 and 0.5 μg of pcDNA-MCAF1 was also transfected ([Figure 7](#F7){ref-type="fig"}C). Additionally, transfecting MCAF1 siRNA into 293T cells markedly reduced the intracellular level of MCAF1 ([Figure 8](#F8){ref-type="fig"}A) and decreased the transcriptional activity of the BHLF1 and BMRF1 promoters that is synergistically activated by Rta and Zta 67% and 74%, respectively ([Figure 8](#F8){ref-type="fig"}B). However, MCAF1 siRNA did not affect the activity of the BMLF1 promoter ([Figure 8](#F8){ref-type="fig"}B). Figure 7.MCAF1 and synCergistic activation of transcription by Rta and Zta. (**A**) 293T cells were cotransfected with a reporter plasmid, pBHLF1 or pEAD, and an empty vector, pCMV-3 (CMV), plasmids that expressed Rta (R), Zta (Z) and MCAF1 (M). (**B**) Cells were also cotransfected with pCMV-R, pCMV-Z and 0--0.5 μg of pcDNA-MCAF1. (**C**) A similar study was conducted in BJAB cells. The luciferase activity of the cells was determined 48 h following transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared in duplicate. Figure 8.Knockdown of MCAF1 and synergistic activation. (**A**) 293T cells were transfected with MCAF1 siRNA (lane 2) or control siRNA (lane 1). The expression of MCAF1 was determined by immunoblotting using anti-MCAF1 antibody at 48 h following transfection. The amount of α-tubulin in the cell was used as a control. (**B**) 293T cells were cotransfected with pBHLF1, pEAD, or pBMLF1 with pCMV-R, pCMV-Z and MCAF1 siRNA or control siRNA. The luciferase activity of the cells was determined 48 h following transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared in duplicate.

DISCUSSION
==========

As is generally known, viruses commonly express abundant amounts of lytic proteins during the productive cycle. To achieve this, viruses often use viral-encoded transcription factors to promote the transcription of viral genes. Furthermore, these transcription factors may collaborate with each other to activate transcription synergistically to achieve high levels of expression of proteins that are needed for viral lytic development. For example, the two human cytomegalovirus (HCMV) immediate-early proteins, IE1 and IE2, synergistically activate the HCMV lytic genes ([@B32],[@B33]). The human immunodeficiency virus (HIV) Tat protein is known to interact with PCAF to activate transcription synergistically ([@B34]). In EBV, Rta and Zta are expressed at the onset of the lytic cycle. These two proteins commonly cooperate with each other and activate transcription synergistically ([@B3],[@B5],[@B9],[@B17],[@B18]). Since the binding between Rta and Zta has not been proven experimentally, one model proposes that the simultaneous binding of Rta and Zta to RRE and ZRE, respectively, in a promoter is a prerequisite for synergistic activation ([@B5],[@B19]). However, the model may not accurately explain how the transcription is synergistically activated, since Rta and Zta activate synergistically the BRLF1 promoter, which does not have an RRE ([@B18]). Accordingly, an alternative model suggests that Rta and Zta form a complex through an unidentified protein to activate transcription synergistically ([@B4]).

If the synergistic activation by Rta and Zta involves an intermediary protein, then this protein is likely to be MCAF1 since Rta and Zta simultaneously interact with MCAF1. The evidence for this interaction is that Rta, MCAF1 and Zta bind to ZRE probes *in vitro* ([Figure 1](#F1){ref-type="fig"}B, lanes 3 and 7; [Figure 1](#F1){ref-type="fig"}). This interaction also proceeds *in vivo* since these three proteins can be co-immunoprecipitated ([Figure 2](#F2){ref-type="fig"}); bind to the ZREs in the BHLF1, BHRF1 and BMRF1 promoters, as demonstrated by CHIP analysis ([Figure 3](#F3){ref-type="fig"}); and colocalize in the nucleus ([Figure 4](#F4){ref-type="fig"}). The fact that the BHLF1 promoter includes four ZREs in the *oriLyt*, which are critically involved in the EBV lytic replication, implies that Rta may participate in EBV lytic replication by interacting with MCAF1 and Zta. This study also establishes that the interaction between Rta and Zta depends on domain 1 region in MCAF1, where MBD1, Sp1, and TFIIE also bind ([@B23],[@B24]), since adding a peptide that contains the sequence in this region causes the interaction ([Figure 5](#F5){ref-type="fig"}E).

This study demonstrates that synergistic activation of transcription by Rta and Zta depends on ZRE but not RRE. In the BMRF1 promoter, the region from −172 to +20 contains an RRE and three ZREs ([Figure 6](#F6){ref-type="fig"}A). Results of this study show that mutating the RRE reduces the increase in synergistic activity from 784-fold to 400-fold ([Figure 6](#F6){ref-type="fig"}B). However, the 400-fold increase considerably exceeds those achieved using pCMV-R or pCMV-Z ([Figure 6](#F6){ref-type="fig"}B), indicating that Rta and Zta synergistically activate the mutant promoter in pBMRF1-mRRE. In fact, a similar phenomenon was also observed by an earlier study ([@B5]). This result suggests that, rather than participating in synergistic activation, Rta, when it binds to RRE, acts alone but does not cooperate with Zta to activate transcription. Furthermore, mutating the three ZREs in a promoter, such as pBMRF1-mZRE ([Figure 6](#F6){ref-type="fig"}A), eliminates the increase in synergistic activity from 784-fold to 19-fold ([Figure 6](#F6){ref-type="fig"}B), indicating that after ZREs are mutated, pCMV-R and pCMV-Z no longer activate the promoter synergistically. Moreover, the synergistic activation of the ZRE promoter in pZRE but not the RRE promoter in pRRE ([Figure 6](#F6){ref-type="fig"}D) further supports the fact that the synergistic activation depends on ZRE but not RRE. Additionally, Giot *et al.* ([@B4]) indicated that the DNA-binding domain in Zta is critical to the synergistic activation, supporting the conclusion that ZRE participates in synergistic activation. Earlier studies of synergistic activation have demonstrated that after ZRE is mutated in the BMRF1 promoter, Zta no longer binds to the promoter and Zta that is unbound to the mutant promoter actually inhibits the transcription that is activated by Rta ([@B4],[@B5]). In HCMV, unbound IE1 was also found to inhibit the transcription that is activated by IE2 ([@B32],[@B33]). The inhibition by unbound Zta may explain why cotransfecting pCMV-R and pCMV-Z activates the BMRF1 promoter in pBMRF1-mZRE to an extent that is lower than achieved using pCMV-R ([Figure 6](#F6){ref-type="fig"}B). Since the interaction of Rta with MCAF1 prevents the binding of Rta to RRE ([Figure 1](#F1){ref-type="fig"}C, lane 5) ([@B12]), after the mutation of ZRE, the unbound Zta may form a complex with MCAF1 and Rta, reducing the level of Rta that binds to RRE to activate transcription.

This study demonstrates that MCAF1 participates in synergistic activation by Rta and Zta. In a transient transfection study, expressing MCAF1 increases the synergistic activation of the BHLF1 and BMRF1 promoters in a dose-dependent manner in both 293T and BJAB cells ([Figure 7](#F7){ref-type="fig"}B and C). As MCAF1 is expressed constitutively and abundant in cells ([Figure 4](#F4){ref-type="fig"}), this may explain why overexpressing MCAF1 does not substantially increase the synergy ([Figure 7](#F7){ref-type="fig"}B and C). Additionally, introducing MCAF1 siRNA into the cell reduces the increment in synergistic activity 67% and 74%, respectively ([Figure 8](#F8){ref-type="fig"}B). This finding suggests that Rta and Zta cannot synergistically activate transcription when MCAF1 is insufficient. The reduction of the activation by MCAF1 siRNA cannot be attributed to the likelihood that the siRNA nonspecifically inhibits global transcription since the transcription of BMLF1 is unaffected ([Figure 8](#F8){ref-type="fig"}B). This study also attempted to demonstrate the inhibition of transcription of BMRF1 from the EBV genome by using the same siRNA approach ([Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkq243/DC1)). However, the inhibition was less profound than the results from the transfection study. This observation may be owing to that, in contrast with the plasmids transfected into the cell, the copy number of the EBV DNA is relatively low. The amount of MCAF1 remaining in the cell after siRNA knockdown is probably adequate to sustain the transcription of BMRF1. This study further demonstrates that MCAF1 enhances the transcription of BHLF1 that is activated by Zta from 41.6-fold to 73.7-fold ([Figure 7](#F7){ref-type="fig"}A). Moreover, an MCAF1 knockdown by siRNA reduces the enhancement ([Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkq243/DC1)), indicating that MCAF1 promotes Zta-activated transcription, although not synergistically. Furthermore, although Rta interacts with Sp1 through MCAF1 and enhances Sp1-mediated transcription ([@B12]), Rta and Sp1 do not activate synergistically the transcription of an Sp1 reporter plasmid (data not shown). Similarly, our unpublished data also show that Rta interacts with AP-1 and ATF2 via MCAF1. However, the interaction does not appear to activate transcription synergistically (data not shown). These findings indicate that the interaction between the MCAF1--Rta complex with a protein binding to a promoter does not always result in synergistic activation. Additionally, Francis *et al.* ([@B19]) showed that although an S186A mutation in Zta abolishes the transactivation ability, the mutant protein remains capable of binding to ZRE and collaborates with Rta to activate the transcription of BMRF1 and BRLF1 synergistically. The finding suggests that the binding of Zta to ZRE but not the transactivation capability of Zta is important to the synergistic activation.

Based on our results, we conclude that Rta interacts with Zta on ZRE through MCAF1. In this protein complex, Rta and Zta may act together or recruit additional transcription factors to promote synergistic activation. Synergistic activation of EBV lytic transcription by Rta and Zta is critical to the efficient expression of viral lytic proteins in the lytic cycle. This study demonstrates that formation of a Zta--MCAF1--Rta complex on ZRE is the underlying mechanism that causes synergistic activation, which is critical to EBV lytic development.
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[^1]: ^a^The DNA fragment was inserted into a luciferase reporter vector, pGL2-Basic.

[^2]: ^b^Crossed rectangle represents mutated sequence; arrow, transcription start site.

[^3]: ^c^Although the BMLF1 promoter contains a sequence resembling that of ZRE, the promoter is not activated by Zta ([@B30]).
